Assess the Safety, Tolerability, PK and Anti-tumor Efficacy of DZD2269 in Patients With MCRPC
Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
This study will treat patients with Metastatic Castration Resistant Prostate Cancer who have
progressed following prior therapy. This is the first time this drug has ever been tested in
patients, and so it will help to understand what type of side effects may occur with the drug
treatment. It will also measure the the levels of drug in the body and preliminarily assess
its anti-cancer activity as monotherapy.